Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC

Exclusion Criteria

• •Prior treatment with pemetrexed (Alimta) or Bortezomib (Velcade).
• •Patient was treated for another cancer within 3 years before enrollment, with the exception of basal cell carcinoma or cervical cancer in situ.
• •Peripheral neuropathy NCI grade \> 2.
• •Symptomatic or uncontrolled brain metastasis.
• •Radiation therapy to major bone marrow (\> 10% of bone marrow) areas or to target lesions within 30 days prior to study entry.
• •Patient has received other investigational drugs with 14 days before enrollment.
• •Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
• •Any systemic therapy within 21 days prior to study entry.
• •Patient known to be human immunodeficiency virus (HIV)-positive.
• •Patient had a significant cardiac event within 6 months of enrollment
• •History of arrhythmia
• •Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age.
• •QT prolongation with other medications that required discontinuation of that medication.
• •Presence of left bundle branch block (LBBB).
• •QTc ≥480 msec or greater on screening ECG.
• •Patient has hypersensitivity to bortezomib, boron or mannitol.
• •Female patient is pregnant or breast-feeding.